UVA’s Alban Gaultier and former Pharmacology graduate student Dorian A. Rosen found last year that fluvoxamine may stop the deadly inflammation known as sepsis. This discovery led to a recent clinical trial that found that this antidepressant may stop COVID symptoms from worsening. Please visit UVAToday for the full story.

The Pharmacology Department would like to send a huge congrats to the Gaultier Lab for this key contribution towards the treatment of COVID-19!